{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T16:49:24Z","timestamp":1794242964273,"version":"4.9.0"},"reference-count":36,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T00:00:00Z","timestamp":1761782400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hematology Reports"],"abstract":"<jats:p>Myelodysplastic neoplasms represent a diverse group of clonal hematopoietic stem cell disorders characterized by ineffective hematopoiesis, peripheral cytopenias, and an inherent risk of progression to acute myeloid leukemia. Accurate risk assessment and patient stratification are critical to optimizing therapeutic approaches and clinical outcomes. In 2022, significant advancements reshaped both the classification and prognostic stratification of MDSs. The revised WHO Classification introduced crucial genetically defined subtypes, particularly those involving biallelic TP53 inactivation and SF3B1 mutations, shifting the emphasis from traditional morphology-based criteria to molecular ones. Simultaneously, morphological subtypes such as hypoplastic and hyperfibrotic MDSs were established as distinct entities with unique prognostic implications. At the same time, the introduction of the International Molecular Prognostic Scoring System (IPSS-M) provided a more precise prognostic stratification by integrating comprehensive molecular data alongside traditional clinical and cytogenetic parameters. Several validation studies have confirmed IPSS-M\u2019s superior discriminative power compared to previous models, notably IPSS-R, improving predictions regarding overall survival and leukemia transformation. Nevertheless, practical considerations regarding the widespread application of IPSS-M have emerged, including concerns over economic feasibility and accessibility of advanced molecular testing methods, such as extensive Next-Generation Sequencing panels. This review synthesizes the recent literature and critical studies validating these classification and prognostic updates, discussing their clinical impact, practical considerations, and implications for targeted therapeutic strategies. By focusing on molecular pathogenesis, the latest classification systems and prognostic models promise significant advances in patient-specific management, setting the stage for future innovations in treatment and improved patient outcomes.<\/jats:p>","DOI":"10.3390\/hematolrep17060058","type":"journal-article","created":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T05:28:43Z","timestamp":1761888523000},"page":"58","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Navigating the New Era in Myelodysplastic Neoplasms: A Review of Prognostic Implications of the IPSS-M Score and 2022 WHO Classification"],"prefix":"10.3390","volume":"17","author":[{"given":"Mihai-Emilian","family":"Lapadat","sequence":"first","affiliation":[{"name":"Department of Hematology, \u201cCarol Davila\u201d University of Medicine and Pharmacy, 050474 Bucharest, Romania"},{"name":"Clinic of Hematology, Coltea Clinical Hospital, 030171 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oana","family":"Stanca","sequence":"additional","affiliation":[{"name":"Department of Hematology, \u201cCarol Davila\u201d University of Medicine and Pharmacy, 050474 Bucharest, Romania"},{"name":"Clinic of Hematology, Coltea Clinical Hospital, 030171 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicoleta Mariana","family":"Berbec","sequence":"additional","affiliation":[{"name":"Department of Hematology, \u201cCarol Davila\u201d University of Medicine and Pharmacy, 050474 Bucharest, Romania"},{"name":"Clinic of Hematology, Coltea Clinical Hospital, 030171 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-6227-0356","authenticated-orcid":false,"given":"Cristina","family":"Negotei","sequence":"additional","affiliation":[{"name":"Department of Hematology, \u201cCarol Davila\u201d University of Medicine and Pharmacy, 050474 Bucharest, Romania"},{"name":"Clinic of Hematology, Coltea Clinical Hospital, 030171 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrei","family":"Colita","sequence":"additional","affiliation":[{"name":"Department of Hematology, \u201cCarol Davila\u201d University of Medicine and Pharmacy, 050474 Bucharest, Romania"},{"name":"Clinic of Hematology, Coltea Clinical Hospital, 030171 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,10,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"El Hussein, S., and Loghavi, S. (2022). The impact of clonal hierarchy and heterogeneity on phenotypic manifestations of myelodysplastic neoplasms. Cancers, 14.","DOI":"10.3390\/cancers14225690"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1182\/blood.2023020078","article-title":"Diagnosis and classification of myelodysplastic syndromes","volume":"142","author":"Hasserjian","year":"2023","journal-title":"Blood"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1002\/ajh.26984","article-title":"Myelodysplastic syndromes: 2023 update on diagnosis, risk-stratification, and management","volume":"98","year":"2023","journal-title":"Am. J. Hematol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1182\/blood.2019000942","article-title":"Genetics of progression from MDS to secondary leukemia","volume":"136","author":"Menssen","year":"2020","journal-title":"Blood"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1182\/blood-2008-01-134858","article-title":"Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001\u20132004, using data from the NAACCR and SEER programs","volume":"112","author":"Rollison","year":"2008","journal-title":"Blood"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1016\/j.leukres.2011.06.001","article-title":"Incidence and prevalence of myelodysplastic syndromes: Data from the D\u00fcsseldorf MDS registry","volume":"35","author":"Neukirchen","year":"2011","journal-title":"Leuk. Res."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1182\/blood-2012-03-420489","article-title":"Revised International Prognostic Scoring System for myelodysplastic syndromes","volume":"120","author":"Greenberg","year":"2012","journal-title":"Blood"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1111\/bjh.15243","article-title":"Prognostic scoring systems for myelodysplastic syndromes in a population-based setting: A report from the Swedish MDS register","volume":"181","author":"Berggren","year":"2018","journal-title":"Br. J. Haematol."},{"key":"ref_9","first-page":"783","article-title":"Myelodysplastic syndromes: Diagnosis, prognosis, and treatment","volume":"110","author":"Germing","year":"2013","journal-title":"Dtsch. Arztebl. Int."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Travaglini, S., Marinoni, M., Visconte, V., and Guarnera, L. (2024). Therapy-Related Myeloid Neoplasm: Biology and Mechanistic Aspects of Malignant Progression. Biomedicines, 12.","DOI":"10.3390\/biomedicines12051054"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1053\/j.seminhematol.2024.09.004","article-title":"Therapy-related myelodysplastic syndromes and acute myeloid leukemia","volume":"61","author":"Venugopal","year":"2024","journal-title":"Semin. Hematol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1093\/jnci\/djs411","article-title":"Myelodysplastic syndrome and benzene exposure among petroleum workers: An international pooled analysis","volume":"104","author":"Schnatter","year":"2012","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1093\/jnci\/djy143","article-title":"Chinese Center for Disease Control and Prevention\u2013US National Cancer Institute Benzene Study Group. Benzene Exposure Response and Risk of Myeloid Neoplasms in Chinese Workers: A Multicenter Case-Cohort Study","volume":"111","author":"Linet","year":"2019","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Jin, J., Yu, M., Hu, C., Ye, L., Xie, L., Jin, J., Chen, F., and Tong, H. (2014). Pesticide Exposure as a Risk Factor for Myelodysplastic Syndromes: A Meta-Analysis Based on 1,942 Cases and 5,359 Controls. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0110850"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1097\/00001648-200005000-00010","article-title":"Smoking and Myelodysplastic Syndromes","volume":"11","author":"Albin","year":"2000","journal-title":"Epidemiology"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/j.1365-2141.1982.tb08475.x","article-title":"Proposals for the classification of the myelodysplastic syndromes","volume":"51","author":"Bennett","year":"1982","journal-title":"Br. J. Haematol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","article-title":"The 2008 revision of the World Health Organization classification of myeloid neoplasms and acute leukemia: Rationale and important changes","volume":"114","author":"Vardiman","year":"2009","journal-title":"Blood"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: Myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: Integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1182\/blood.V89.6.2079","article-title":"International scoring system for evaluating prognosis in myelodysplastic syndromes","volume":"89","author":"Greenberg","year":"1997","journal-title":"Blood"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.hoc.2010.02.005","article-title":"Prognostic classification and risk assessment in myelodysplastic syndromes","volume":"24","author":"Cazzola","year":"2010","journal-title":"Hematol. Oncol. Clin. N. Am."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"S60","DOI":"10.1016\/j.clml.2015.03.011","article-title":"Validation of the lower-risk MD Anderson Prognostic Scoring System for patients with myelodysplastic syndrome","volume":"15","author":"Komrokji","year":"2015","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2659","DOI":"10.1002\/cncr.26567","article-title":"Validation of the MD Anderson Prognostic Risk Model for patients with myelodysplastic syndrome","volume":"118","author":"Komrokji","year":"2012","journal-title":"Cancer"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1111\/bjh.12884","article-title":"Comparison of the prognostic utility of the revised International Prognostic Scoring System and the French Prognostic Scoring System in azacitidine-treated patients with myelodysplastic syndromes","volume":"166","author":"Zeidan","year":"2014","journal-title":"Br. J. Haematol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"EVIDoa2200008","DOI":"10.1056\/EVIDoa2200008","article-title":"Molecular International Prognostic Scoring System for myelodysplastic syndromes","volume":"1","author":"Bernard","year":"2022","journal-title":"NEJM Evid."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.1038\/s41375-022-01718-7","article-title":"Comparison of the revised 4th (2016) and 5th (2022) editions of the World Health Organization classification of myelodysplastic neoplasms","volume":"36","author":"Zhang","year":"2022","journal-title":"Leukemia"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1182\/blood-2015-03-633537","article-title":"SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts","volume":"126","author":"Malcovati","year":"2015","journal-title":"Blood"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1182\/blood.2020004850","article-title":"SF3B1-mutant MDS as a distinct disease subtype: A proposal from the International Working Group for the Prognosis of MDS","volume":"136","author":"Malcovati","year":"2020","journal-title":"Blood"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1056\/NEJMoa1908892","article-title":"Luspatercept in patients with lower-risk myelodysplastic syndromes","volume":"382","author":"Fenaux","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/S2352-3026(24)00203-5","article-title":"Luspatercept versus epoetin alfa in ESA-naive, transfusion-dependent, lower-risk MDS (COMMANDS): Primary analysis of a phase 3, open-label, randomised, controlled trial","volume":"11","author":"Santini","year":"2024","journal-title":"Lancet Haematol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"4088","DOI":"10.1182\/blood-2022-159335","article-title":"A retrospective validation study comparing the IPSS-M and IPSS-R risk stratification scores in primary and secondary myelodysplastic syndrome","volume":"140","author":"Sabile","year":"2022","journal-title":"Blood"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1038\/s41375-023-01831-1","article-title":"Risk prediction in MDS: Independent validation of the IPSS-M\u2014Ready for routine?","volume":"37","author":"Baer","year":"2023","journal-title":"Leukemia"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1182\/blood-2022-163634","article-title":"Real-world validation of the Molecular International Prognostic Scoring System for myelodysplastic syndromes","volume":"140","author":"Sauta","year":"2022","journal-title":"Blood"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"9813","DOI":"10.1182\/blood-2022-170980","article-title":"Assessment of the Molecular International Prognostic Scoring System risk stratification model in therapy-related myelodysplastic syndromes","volume":"140","author":"Aguirre","year":"2022","journal-title":"Blood"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"6966","DOI":"10.1182\/blood-2022-168705","article-title":"IPSS-M Applicability and Clinical Impact in Decision-Making Process in Real-Life Clinical Practice","volume":"140","author":"Palomo","year":"2022","journal-title":"Blood"}],"container-title":["Hematology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2038-8330\/17\/6\/58\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T06:05:45Z","timestamp":1761890745000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2038-8330\/17\/6\/58"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,30]]},"references-count":36,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["hematolrep17060058"],"URL":"https:\/\/doi.org\/10.3390\/hematolrep17060058","relation":{},"ISSN":["2038-8330"],"issn-type":[{"value":"2038-8330","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,30]]}}}